Evidence map›Paper›PMID 33131270›Full record

ArticleEuropean journal of histochemistry : EJH2020

Swertiamarin suppresses proliferation, migration, and invasion of hepatocellular carcinoma cells <em>via</em> negative regulation of FRAT1.

Shufeng Xiao, Haoren Tang, Yao Bai, Renchao Zou, Zongfang Ren, Xuesong Wu, Zhitian Shi, Song Lan, Wei Liu, Tiangen Wu and 2 more

Open access · goldAbstract read
In one paragraph

Article in European journal of histochemistry : EJH, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Mechanism ofNan fang yi ke da xue xue bao = Journal of Southern Medical University · 2025
    Article
  5. Review
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Shufeng XiaoDepartment of Hepatobiliary Surgery, the Second Affiliated Hospital of Kunming Medical University, Kunming; Department of General Surgery, Puer People's Hospital, Puer. xsf7644@163.com.
Haoren TangDepartment of Gastroenterological Surgery, the Second Affiliated Hospital of Kunming Medical University, Kunming. tanghaoran1190@126.com.
Yao BaiSchool of Medicine, Yunnan University, Kunming. yy_xx08@163.com.
Renchao ZouDepartment of Hepatobiliary Surgery, the Second Affiliated Hospital of Kunming Medical University, Kunming 2Department of General Surgery, Puer People's Hospital, Puer. zourenchao@126.com.
Zongfang RenDepartment of Critical Care Medicine, the Second Affiliated Hospital of Kunming Medical University, Kunming. renzongfang1191@163.com.
Xuesong WuDepartment of Gastroenterological Surgery, the Second Affiliated Hospital of Kunming Medical University. kmykdwxs_139@163.com.
Zhitian ShiDepartment of Hepatobiliary Surgery, the Second Affiliated Hospital of Kunming Medical University, Kunming. szt_1004@163.com.
Song LanDepartment of Pathology, Puer People's Hospital, Puer. lantian508@126.com.
Wei LiuDepartment of Hepatobiliary Surgery, The People's Hospital of Chuxiong Yi Autonomous Prefecture, the Fourth Affiliated Hospital of Dali University, Chuxiong. awei_0307@163.com.
Tiangen WuDepartment of Hepatobiliary Surgery, the Second Affiliated Hospital of Kunming Medical University, Kunming. wutiangen001@163.com.
Cheng ZhangDepartment of Hepatobiliary Surgery, the Second Affiliated Hospital of Kunming Medical University, Kunming. zhangcheng_tnt@126.com.
Lin WangDepartment of Hepatobiliary Surgery, the Second Affiliated Hospital of Kunming Medical University, Kunming. linwang705@gmail.com.
Kunming Medical University · CNPuer University · CNThe Fourth People's Hospital of Ningxia Hui Autonomous Region · CNYunnan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Studies have shown that swertiamarin (STM) has multiple biological activities, but its anti-tumour effects and molecular mechanisms are still unclear. The present research aimed to validate the STM's impacts on the proliferation, migration, and invasion of hepatocellular carcinoma (HCC) cells, and to study its potential mechanism. Two HCC cell lines were treated with STM. Tumour growth was observed by the mouse tumour xenografts model. HCC cell lines stably expressing T-cell lymphomas 1 (FRAT1) were generated by lentivirusmediated overexpression. Cell viability, proliferation, migration, and invasion were observed using Cell Counting Kit-8 (CCK8), the xCELLigence Real-Time Cell Analyzer system (RTCA), and transwell analysis, respectively. Quantitative real-time polymerase chain reaction (qRT-PCR) and Western blotting were used to observe the expression of FRAT1 and proteins related to the Wnt/β-catenin signalling pathway. Tumour growth was inhibited by STM in vivo. STM suppressed the proliferation, migration, and invasion of HCC cells. STM negatively regulated FRAT1 expression, whereas overexpressed FRAT1 blocked the anti-tumour function of STM. The results revealed that STM suppressed the FRAT1/Wnt/β-catenin signalling pathway. The findings of this study provide new insights into investigation of therapeutic strategies against HCC.

Indexed as

Adaptor Proteins, Signal TransducingAnimalsAntineoplastic AgentsCarcinoma, HepatocellularCell Line, TumorCell MovementCell ProliferationDown-RegulationGene Expression Regulation, NeoplasticHumansIridoid GlucosidesLiver NeoplasmsMaleMice, Inbred BALB CMice, NudeProto-Oncogene ProteinsAdaptor Proteins, Signal TransducingAntineoplastic AgentsFRAT1 protein, humanIridoid GlucosidesProto-Oncogene ProteinsPyronesswertiamarin

Identifiers

PMID33131270
PMCPMC7586251
OpenAlexW3094593834

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.